NCT04584515View on ClinicalTrials.gov

IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

March 8, 2021

Study Completion Date

May 27, 2021

Conditions
Solid Tumor
Interventions
DRUG

IMP4297 40 mg

IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297

DRUG

IMP4297 100 mg

IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297

Trial Locations (1)

201210

Impact Therapeutics, Inc., Shanghai

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT04584515 - IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter